Unit of Interventional Radiology, European Institute of Oncology, Via Ripamonti 435, 2041, Milan, Italy.
Cardiovasc Intervent Radiol. 2012 Dec;35(6):1372-9. doi: 10.1007/s00270-012-0341-0. Epub 2012 Jan 21.
This retrospective study evaluated the feasibility, efficacy, and safety of combining transcatheter arterial embolization (TAE) with radiofrequency thermal ablation (RFA) in a single session for the treatment of technically unresectable liver-only malignancies.
From May 2006 to January 2011, a total of 30 patients affected by liver metastases with single or multiple unresectable liver-only lesions underwent a combined treatment with TAE followed by RFA in the same session, for a total of 36 treated lesions. Patients were extrapolated from a cohort of patients discussed within the weekly institutional tumor board. TAE was performed by using 100 μm microspheres; RFA was performed immediately after TAE by positioning the electrode needle via ultrasound and/or computed tomographic guidance. Local tumor responses and procedure-related complications were evaluated.
Completion of both procedures was obtained in all patients for all 36 lesions. Liver lesions had a maximum axial diameter ranging 16-59 mm. Postintervention unenhanced ablated areas ranged 28-104 mm in maximum axial diameter. Safety margins ranged 1-30.5 mm. Complete response, defined as complete devascularization at computed tomography, was obtained in all treated lesions for a maximum period of 12 months. Tumor relapse was observed in one patient at 12 months. Sixteen patients developed new liver lesions or progressive systemic disease during follow-up. Nine patients were still disease-free. Seven patients died as a result of systemic progressive disease. One major treatment-related complication was observed.
In patients with technically unresectable liver-only malignancies, single-session combined TAE-RFA is an effective and safe treatment.
本回顾性研究评估了在单次治疗中联合经导管动脉栓塞术(TAE)和射频热消融术(RFA)治疗技术上不可切除的单纯性肝脏恶性肿瘤的可行性、疗效和安全性。
2006 年 5 月至 2011 年 1 月,共 30 例肝转移患者,有单发或多发不可切除的单纯性肝脏病变,在同一次治疗中接受了 TAE 联合 RFA 治疗,共治疗 36 个病灶。患者是从每周机构肿瘤委员会讨论的患者队列中推断出来的。TAE 采用 100μm 微球进行;TAE 后立即通过超声和/或计算机断层扫描引导定位电极针进行 RFA。评估局部肿瘤反应和与程序相关的并发症。
所有 36 个病灶均成功完成了两种程序。肝病变的最大轴向直径为 16-59mm。介入后未增强的消融区最大轴向直径为 28-104mm。安全边界为 1-30.5mm。所有治疗的病灶在最大 12 个月时间内均获得完全反应,定义为 CT 完全血管化。1 例患者在 12 个月时出现肿瘤复发。16 例患者在随访期间出现新的肝病变或进展性全身疾病。9 例患者仍无疾病。7 例患者因全身进展性疾病而死亡。观察到 1 例与治疗相关的严重并发症。
在技术上不可切除的单纯性肝脏恶性肿瘤患者中,单次联合 TAE-RFA 是一种有效且安全的治疗方法。